NCT00073554CompletedPhase 2
A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- ARCA Biopharma, Inc.
- Enrollment
- 100
- Locations
- 1
Study Overview
Brief Summary
This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell DiseaseSickle Cell DiseaseNCT00445978BioMarin Pharmaceutical32
Terminated
Phase 2
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03567616AbbVie8
Completed
Phase 1
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT00951665Genentech, Inc.107
Completed
Phase 2
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)Frown LinesNCT03786770Revance Therapeutics, Inc.61
Completed
Phase 1
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)Graft Versus Host DiseaseNCT01379209Regimmune Corporation68